What the new Argentina guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Practice Dispatch
What the new Norway guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The pharmacy regulator in Norway has issued counselling standards for initiation of GLP-1 receptor agonist therapy, specifying what must be covered at the point of supply: device technique, expected adverse effects, what to do about a missed dose, storage, sharps disposal, and — notably — what happens if treatment stops.
The titration document sets out three permissible responses to unresolved symptoms at a given dose: hold at the current dose for a further interval, return to the previous dose, or discontinue. It declines to specify a maximum hold duration, on the stated grounds that no evidence supports one.
The evidence base for most practical questions in this field is thin, and the better guidance documents say so explicitly rather than manufacturing a recommendation grade. The Journal reports the stated evidence quality alongside the recommendation, because a strong recommendation on low-quality evidence is a different object from a strong recommendation on high-quality evidence.
Peter Malinowski, former state board of pharmacy inspector, noted who the document does not reach. "None of my patients who buy online will ever see this. That population is entirely outside the guidance system."
The Journal has added the document to its practice index with the stated evidence grades recorded. We report guidance from the document, not from the accompanying summary.
Related coverage
One receptor, several signals: the case for reading retatrutide as a biased agonist
What the in-vitro data supports, what it does not, and where the extrapolation to a person begins.
New Zealand caps semaglutide prescribing to 13 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Dose-limiting: a definition worth being strict about
Roughly four to seven per cent of trial participants discontinued for adverse events, mostly gastrointestinal, mostly during escalation. That is the empirical size of the…
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Four millimetres is enough, and the data says so
A 4 mm needle at ninety degrees without a skin pinch is adequate for essentially all adults. The persistence of 12.7 mm needles in this market is habit, not reasoning.